This assay is based on epigenetic changes associated with the risk of PC development existing/occurring adjacent to tumor foci (halo effect) and evaluates quantitatively the DNA methylation level of GSTP1, APC, and RASSF1. The gene discussed is GSTP1; the disease is pachyonychia congenita.